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Abstract 1 
Chronic diabetic foot ulcers are frequently colonised and infected by 2 
polymicrobial biofilms that ultimately prevents healing. In this study, we aimed to 3 
create a novel in vitro inter-kingdom wound biofilm model on complex hydrogel-4 
based cellulose substrates to test commonly used topical wound treatments. 5 
Inter-kingdom triadic biofilms composed of Candida albicans, Pseudomonas 6 
aeruginosa, and Staphylococcus aureus were shown to be quantitatively greater 7 
in this model compared to a simple substrate when assessed by conventional 8 
culture, metabolic dye and live dead qPCR. These biofilms were both structurally 9 
complex and compositionally dynamic in response to topical therapy, so when 10 
treated with either chlorhexidine or povidone iodine principal component 11 
analysis revealed that the 3-D cellulose model was minimally impacted 12 
compared to the simple substrate model. This study highlights the importance of 13 
biofilm substrate and inclusion of relevant polymicrobial and inter-kingdom 14 
components, as these impact penetration and efficacy of topical antiseptics.  15 
  16 
 3 
Background 1 
Chronic wounds are associated with unacceptably high morbidity and mortality 2 
rates, in addition to being a significant economic burden to the National Health 3 
Service (NHS) in the UK. It is estimated that the NHS spends in the region of 4 
£900 million per year on diabetic foot ulcer treatments and resultant amputations 5 
(Hex et al. 2012). Infection risk is one of the overriding factors driving these costs 6 
and complications, and the capacity of endogenous and exogenous 7 
microorganisms to form complex biofilms within these compromised skin 8 
environments hinders chemotherapeutic management (Alavi et al. 2014).  9 
 10 
Pathogenic biofilms are frequently associated with chronic wounds (James et al. 11 
2008, Neut et al. 2011). These structures complicate treatment strategies due to 12 
enhanced adaptive resistance profiles, primarily driven by the physical 13 
composition, including the production of extracellular matrix (ECM) that prevents 14 
diffusion of antimicrobials into the biofilm (Davies 2003, Pozo and Patel 2007, 15 
Ramage et al. 2012a). ECM-associated degradative enzymes, hypermutability, 16 
and persister cells, are just a few examples of how these complex communities 17 
survive and adapt to antimicrobial challenge (Davies 2003, Høiby et al. 2010, 18 
Pozo and Patel 2007, Ramage, et al. 2012a). Complicating chemotherapeutic 19 
intervention even further is the polymicrobial nature of the biofilms found in 20 
diabetic foot ulcers (Smith et al. 2016). Moreover, increasing evidence that 21 
yeasts and moulds play important contributory roles in exacerbating infections 22 
suggests inter-kingdom biofilms deserve consideration (Peters et al. 2012). 23 
 24 
S. aureus and P. aeruginosa are the two most frequently isolated bacterial 25 
species from such chronic and difficult-to-treat biofilm infections (Citron et al. 26 
2007, Hartemann‐Heurtier et al. 2004, MacDonald et al. 2002). They are often 27 
co-isolated and are associated geographically within the wound site (Fazli et al. 28 
2009). In contrast to bacteria, despite reports their importance, the role of 29 
pathogenic fungi in wound biofilms, are relatively under-investigated and 30 
underappreciated clinical entities (Appelgren et al. 2002, Dowd et al. 2011, 31 
MacDonald, et al. 2002, Santucci et al. 2003, Sun 2010, Weinstein and Mayhall 32 
2003). Candida species are the primary fungal pathogen isolated from these 33 
 4 
infections, although this organism rarely colonises healthy intact skin (Grice and 1 
Segre 2011). Several models have been described in recent years that have 2 
examined these paradigm nosocomial pathogens in triadic systems (Hoekstra 3 
et al. 2016, Kart et al. 2014). Though a caveat to the utility and translation of 4 
these models is the basic 2-dimensional nature of the substrates used, which 5 
are not at all representative of a wound environment (Hill et al. 2010, Hoekstra, 6 
et al. 2016, Kart, et al. 2014). The development of cellulose matrix based models 7 
supported by hydrogels that better mimic the consistency of the wound surface 8 
enables biofilms to form in a 3-dimensional matrix. Using either poloxamer, 9 
collagen, or agarose hydrogel, a complex hydrated structure is formed which 10 
induces the development of the biofilm phenotype (Clutterbuck et al. 2007, 11 
Harrison et al. 2015, Percival et al. 2007, Strathmann et al. 2000). The main 12 
applicability and translation usefulness of these model systems lies in their utility 13 
in the development and testing of antimicrobial anti-biofilm molecules. To date, 14 
these models have tended to focus on mono-species biofilms.   15 
 16 
Systemic antibiotics are commonly used to treat chronic wounds, yet there is 17 
controversy over their usage and rising concerns over the development of 18 
antimicrobial resistant organisms (Atiyeh et al. 2009, O'meara et al. 2001). 19 
Topical wound washes and ointments are often recommended as an alternative 20 
to, or in combination with, systemic treatment (Atiyeh, et al. 2009, Snell et al. 21 
2013). Chlorhexidine (CHX) and povidone iodine (PVP-I) are two of the most 22 
commonly used clinically due to their high levels of biocidal activity (Atiyeh, et al. 23 
2009, O'meara, et al. 2001).  24 
 25 
The aims of the present study were therefore to develop a polymicrobial inter-26 
kingdom in vitro biofilm model on complex substrates that can be used to test 27 
clinically relevant antimicrobial therapeutics. Here we show for the first time the 28 
use of a novel biofilm substrate that can be adapted to represent a wide variety 29 
of wound infection biofilms, and its application for chronic wound biofilm research.  30 
Methods 31 
Culture conditions and standardisation 32 
 5 
A selection of characterised laboratory strains were used in this study, including 1 
the bacteria P. aeruginosa PA14 (Rahme et al. 1995), S. aureus Newman’s  2 
strain (Duthie and Lorenz 1952) and the yeast Candida albicans SC5314 (Fonzi 3 
and Irwin 1993). Both bacteria were grown and maintained at 37°C on Luria agar 4 
(Sigma-Aldrich, Dorset, UK), while C. albicans was grown and maintained at 5 
30°C on Sabouraud dextrose agar (SAB [Sigma-Aldrich, Dorset, UK]). All 6 
isolates were stored indefinitely in Microbank® vials (Pro-Lab Diagnostics, 7 
Cheshire, UK) at -80°C.  8 
Overnight broths of P. aeruginosa and S. aureus were prepared in 10 mL Luria 9 
broth ([LB] Sigma-Aldrich, Dorset, UK) at 37°C and C. albicans was propagated 10 
in 10 mL yeast peptone dextrose broth (YPD [Sigma-Aldrich, Dorset, UK]) at 11 
30°C at 150 rpm. Overnight cultures were washed twice by centrifugation (1600 12 
x g) and resuspended in 10 mL phosphate buffered saline (PBS). All cultures 13 
were standardised and adjusted to 1 × 108 cells/mL, using optical density at 590 14 
nm for bacterial strains and a haemocytometer for C. albicans.  15 
 16 
Hydrogel preparation 17 
Hydrogels were composed of 10% 3-sulfopropyl acrylate potassium salt, 0.95% 18 
v/v poly(ethylene glycol) deacrylate (PEG), 0.01% v/v 1- hydroxycyclohexyl 19 
phenyl ketone, with the addition of 50% heat-inactivated horse serum ([HS] 20 
Thermo Fisher Scientific, Loughborough, UK) in sterile water to the final volume. 21 
To a 12-well flat-bottomed microtiter plates (Corning Incorporated, NY, USA), 2 22 
mL of hydrogel was added to each well before being polymerised under a 366 23 
nm ultraviolet (UV) Lamp (Camag, Hungerford, UK) for 30 min within a class II 24 
laminar flow hood. These polymerised hydrogels were then stored at 4°C until 25 
required, for up to one week. 26 
Biofilm development and antimicrobial therapy 27 
All organisms were standardised to a final working concentration of 1 × 106  28 
cells/mL in 50% v/v HS (Life Technologies, Paisley, UK) for biofilm development. 29 
For viability and biomass assays (described below), 200 µL of single species 30 
 6 
and triadic species suspensions were added to 96-well flat-bottomed microtiter 1 
plates (Corning Incorporated, NY, USA). For quantitative polymerase chain 2 
reaction (qPCR) and viable cell counting, 500 µL of cultures were added to 3 
Thermanox™ coverslips (13 mm diameter, Fisher Scientific) contained within 24 4 
well plates (Corning, NY, USA). Biofilms were incubated at 37°C for 24 h to 5 
develop. All procedures were carried out in a class II laminar flow hood. For 6 
biofilm development on hydrogels, organisms were standardised to a 1 × 106  7 
cells/mL in PBS and added to sections of cellulose matrix (1.25 cm²) (IPS 8 
Converters, Oldham, UK). Following initial incubation at 37°C with agitation for 9 
2 h, the matrix was then placed on top of the hydrogel surface and incubated at 10 
37°C for 24 h. Negative controls containing no inoculum were also included. All 11 
testing was carried out in triplicate, on three separate occasions. Following 12 
biofilm development, cells were washed twice with PBS to remove any non-13 
adherent cells before treatment with 10% w/v PVP-I (Sigma) or 0.05% v/v CHX 14 
(Sigma) for a further 24 h at 37°C. Untreated controls were also included.  15 
 16 
Assessment of treatment using conventional quantitative culture 17 
To assess the viability of the organisms contained within the biofilm, viable cell 18 
counting was performed. Following treatment, biofilms were sonicated in 1 mL 19 
PBS, from Thermanox™ coverslips or hydrogel cellulose matrix at 35 kHz for 10 20 
min to remove the biomass, as described previously (Ramage et al. 2012b), prior 21 
to the Miles and Misra technique (Miles et al. 1938). Decimal serial dilutions were 22 
plated on LB and SAB agar, which were incubated at 37°C and 30°C, 23 
respectively for 72 h for Thermanox™ coverslips, and 48 h for hydrogel. The 24 
number of colonies were counted and represented as total bacteria and total 25 
yeast colony forming units (CFU) per mL.  26 
 27 
Assessment of treatments using quantitative viability assays 28 
Following treatment, biofilms were washed twice with PBS before biofilm viability 29 
and biomass were quantified. Viability was assessed by the AlamarBlue® assay 30 
(Invitrogen, Paisley, UK), as per manufacturer’s instructions (Kirchner et al. 31 
 7 
2012). Absorbance was measured spectrophotometrically at 570 nm and the 1 
reference wavelength at 600 nm (FluoStar Omega, BMG Labtech). All assays 2 
were performed in triplicate, on three separate occasions. 3 
 4 
Assessment of treatment using live/dead quantitative PCR 5 
Viability based qPCR, a technique shown to differentiate between viable and 6 
dead cells (Alvarez et al. 2013, Sanchez et al. 2013, Sanchez et al. 2014, Sherry 7 
et al. 2016), was used to assess the composition and viability of the biofilms at 8 
a molecular level. Samples were prepared as previously described by our group 9 
using propidium monoazide (PMA), a DNA intercalating dye, which prevents 10 
DNA from cells with compromised membranes from being detected by PCR 11 
(Sherry, et al. 2016). Briefly, biofilms were sonicated from Thermanox™ 12 
coverslips or cellulose matrix, 50 μM of PMA was added to each sample before 13 
incubation in the dark for 10 min to allow dye uptake. To permit binding of the 14 
PMA, samples were exposed to a 650 W halogen light for 5 min. DNA was then 15 
extracted using the QIAamp DNA mini kit, as per manufacturer’s instructions 16 
(Qiagen, Crawley, UK). Controls containing no PMA were also included for each 17 
sample to determine total biomass.  18 
Following DNA extraction, qPCR was used to enumerate both the live and total 19 
cells of each species remaining in the biofilm following each treatment. In brief, 20 
1 μL of extracted DNA was added to a mastermix which contained 10 μL Fast 21 
SYBR® Green Master Mix (Life Technologies, Paisley, UK), 7 μL water and 1 μL 22 
of 10 μM forward and reverse primers for each bacterial or fungal species. 23 
Primer sequences are shown in Table 1. The thermal profile of 95°C for 20 s 24 
followed by 40 cycles of 3 s at 95C, and 30 s at 60C was used in this study. 25 
Three independent replicates for each treatment were analysed in duplicate 26 
using Step One Real-Time PCR system and software (Life Technologies, 27 
Paisley, UK). Samples were quantified to calculate the colony forming equivalent 28 
(CFE) based upon a standard curve per reaction performed.  29 
 30 
 8 
Scanning electron microscopy 1 
Biofilms were grown on Thermanox™ coverslips or hydrogel cellulose matrix 2 
and treated, as previously described. Biofilms were washed twice with PBS, 3 
before being fixed in 2% para-formaldehyde, 2% glutaraldehyde, 0.15M sodium 4 
cacodylate, and 0.15% w/v alcian blue, at pH 7.4, and prepared for SEM as 5 
previously described (Erlandsen et al. 2004). The specimens were sputter-6 
coated with gold and viewed under a JEOL JSM-6400 scanning electron 7 
microscope. 8 
 9 
Statistical analysis 10 
Graph production, data distribution and statistical analysis were performed using 11 
GraphPad Prism (version 6; La Jolla, CA, USA). Unpaired t-tests were used to 12 
establish significant differences between treatments and substrate types for 13 
viability assay scores and CFEs. Percentage viability scores were log 14 
transformed before statistical analysis took place. For conventional quantitative 15 
culture, Mann-Whitney test was used. Statistical significance was achieved if 16 
P<0.05. Next, viable composition datasets were reduced by log2 transformation 17 
so as to carry out principal component analysis (PCA) using PAST software 18 
(Hammer O 2001). A scree plot was used to determine how many components 19 
emerged. To determine if statistically distinct clusters formed on the PCA plots, 20 
new variables were created for each principle component by using the factor 21 
loadings as regression coefficients, producing a score for each sample. These 22 
scores were then used as outcome variables to compare between groups using 23 
an unpaired t-test. 24 
25 
 9 
Results 1 
Standard 2-D biofilm models show antibacterial agent efficacy in mono-2 
species, while triadic biofilms support some resistance 3 
Firstly, we wanted to establish a baseline using a typical substrate used for in 4 
vitro biofilm studies, i.e. a 2-D polystyrene model. Here we tested two key topical 5 
agents using conventional culture, and based upon this methodology PVP-I was 6 
shown to be the most effective treatment, completely eradicating the bacterial 7 
and yeast biofilm burden of all mono-cultures (P<0.0001) (Figure 1A). In addition, 8 
CHX was equally active against P. aeruginosa mono-culture biofilms and 9 
bacteria in the triadic species biofilms, significantly reducing total bacterial 10 
counts by >6 log10 (Figures 1A and 1B). S. aureus and C. albicans mono-species 11 
biofilms were also reduced by CHX treatment (Figure 1A), but only by >2 log10  12 
(P<0.05, P<0.001, respectively). However, in the 2-D triadic model yeast counts 13 
were completely unaffected (Figure 1B). Using soluble metabolic dyes (Figure 14 
1C), in the 2-D model C. albicans and P. aeruginosa mono-culture viability was 15 
significantly reduced by both PVP-I and CHX (P<0.0001). CHX was able to 16 
significantly inhibit S. aureus biofilms (P<0.05), but PVP-I showed no significant 17 
reduction. In contrast, in the triadic culture both CHX and PVP-I caused 18 
significant decreases in viability (P<0.0001).  19 
 20 
Molecular analysis reveals reservoirs of viable cells remain after treatment 21 
of 2-D mono-species and triadic biofilms 22 
The techniques described above are subjective in terms of species-specific 23 
quantification, so given these limitations we decided to employ a molecular 24 
approach, enabling determination of the precise viable composition of biofilms 25 
following active exposure. Despite culture and metabolic evaluation showing a 26 
significant reduction in the viability of all biofilms, viable quantitative analysis by 27 
qPCR revealed a significant number of cells are retained within each biofilm 28 
(Figure 2 and 3). Molecular analysis consistently showed higher reductions with 29 
PVP-I compared to CHX treatment in both substrates tested.  30 
 10 
C. albicans mono-species total cell count was significantly reduced with both 1 
PVP-I (P<0.0001) and CHX (P<0.001) treatment (Figure 2A). The number of live 2 
cells remaining within those treated biofilms was 13% (P<0.0001) and 23% 3 
(P<0.01), respectively. S. aureus mono-species total cell count was also 4 
significantly reduced (88.5%) with PVP-I (P<0.0001), with only 2% live cells 5 
remaining (P<0.0001) (Figure 2B). CHX treatment, however, showed no 6 
difference to the control for both total and live cells (P>0.05). P. aeruginosa 7 
mono-species biofilms were also affected by the two treatments (Figure 2C). P. 8 
aeruginosa mono-species total cells were significantly reduced by PVP-I (77%, 9 
P<0.01), and live cells reduced by 98% (P<0.05). CHX treatment appeared to 10 
cause a significant increase in total cell count (P<0.01), though a slight decrease 11 
in live cells (P>0.05).   12 
The triadic species biofilms were again more effectively treated by PVP-I 13 
compared to CHX (Figure 3). The total cell count on the 2-D model was 14 
significantly reduced by PVP-I (92%, P<0.0001; Figure 3B). Live cells were 15 
similarly reduced compared to untreated biofilms (98%, P<0.001; Figure 3A). 16 
CHX caused a significant increase in total cells, rising by ~2.5 times (P<0.0001), 17 
whereas live cells marginally decreased (20%, P>0.05; Figure 3C). 18 
SEM analysis was used to analyse the biofilm architecture ± treatment (Figure 19 
3). In the 2-D model C. albicans was mainly hyphae, acting as a scaffold to which 20 
the bacteria tended to co-aggregate upon (see insert magnification). The cell 21 
density within the biofilm was reduced by both treatments, although more so with 22 
PVP-I. 23 
 24 
3-D substrates support culturably greater quantities of mono-species and 25 
triadic biofilm cells with enhanced resistance to CHX and PVP-I 26 
Using conventional culture, the 3-D cellulose matrix model, with PVP-I treatment 27 
(Figure 4A) significantly reduced C. albicans, S. aureus, and P. aeruginosa 28 
monocultures (P<0.0001), whereas CHX was ineffective for both C. albicans and 29 
P. aeruginosa (P>0.05). S. aureus, however, was significantly decreased by 30 
CHX (P<0.0001; Figure 4A). In the triadic hydrogel model, yeasts and bacteria 31 
 11 
were significantly reduced by PVP-I (P<0.0001), but not CHX (P>0.05; Figure 1 
4B). The metabolic assays confirmed these results (Figure 4C), with both C. 2 
albicans and S. aureus monocultures were significantly reduced by the two 3 
treatments (P<0.0001). P. aeruginosa and triadic cellulose matrix biofilms, 4 
although both significantly reduced with PVP-I treatment (P<0.0001), were 5 
seemingly unaffected by CHX treatment, (P>0.05). 6 
 7 
Molecular analysis shows 3-D substrates support greater total and viable 8 
quantities of mono-and triadic species biofilm cells with enhanced 9 
resistance to CHX and PVP-I 10 
Overall, the treatments on 3-D cellulose matrix mono-species biofilms showed 11 
similar efficacy patterns to the 2-D model, although, 3-D cellulose matrix models 12 
generally had higher numbers of total and viable cells detected by qPCR (P<0.05) 13 
(Figure 5). C. albicans mono-culture total cell count was reduced by 72% by 14 
PVP-I (P<0.01), whereas CHX was less effective with a 28% reduction (P>0.05) 15 
(Figure 5A). The live cell count within these biofilms was significantly reduced 16 
by 98% and 61% after PVP-I (P<0.001) and CHX treatment (P<0.05), 17 
respectively. Both total and live cell counts for S. aureus were reduced by 18 
approximately 88% by PVP-I (P<0.001) and 98% (P<0.05), respectively (Figure 19 
5B). Treatment with CHX was ineffective for total and live cells (P>0.05). CHX 20 
reduced P. aeruginosa total cells by only 15%, and viable cells were unaffected 21 
(P>0.05) (Figure 5C). PVP-I, however, was significantly effective reducing total 22 
cell count by 84% (P<0.001) and live cell count by 95% (P<0.001).  23 
The triadic 3-D model showed a total cell count reduction by 94% with PVP-I 24 
treatment (P>0.05; Figure 6B), and 70% with CHX (P>0.05; Figure 6C). Viable 25 
cell counts were reduced further by PVP-I (97%, P<0.001), whilst CHX was less 26 
effective (22%, P>0.05). 27 
Based the SEM images, it can be clearly shown that there is an increased cell 28 
number on the 3-D substrates, irrespective of treatment. The fibrous nature of 29 
the cellulose matrix creates a greater surface area. Interestingly, in the 3-D 30 
model C. albicans is observed mainly as yeast cells, which is reflected in the 31 
 12 
viable cell numbers reported above. However, on the 3-D substrate the dominant 1 
morphotype was suggestive of P. aeruginosa.  2 
 3 
Statistical analysis reveals significant differences between treatments and 4 
biofilm substrates 5 
The 3-D model was shown to consistently support significantly greater quantities  6 
of cells than that of the 2-D model. This was shown by both conventional culture 7 
and viability assays (P<0.01), and further confirmed by molecular analysis 8 
(P<0.001). There were some compositional differences in the triadic model  9 
revealed by live/dead qPCR, where both S. aureus and C. albicans decreased 10 
in the 3-D model (P<0.0001, P<0.05, respectively). SEM provided further 11 
evidence that irrespective of treatment and substrate, a significant level of 12 
biomass is retained, though notably more upon the cellulose 3-D matrix.   13 
Further to this, there were also significant differences observed between the two 14 
models after treatment. Conventional culture, viability assays, and molecular 15 
analysis revealed that CHX was less effective in the cellulose matrix model 16 
(P<0.05). PVP-I was similarly effective in both models, with higher recalcitrance 17 
observed in the 3-D model for P. aeruginosa (P<0.05), and the bacterial 18 
component of the triadic biofilm (P<0.01). Proportional composition differences 19 
in the 3-D triadic biofilm were observed after both after CHX (P<0.0001) and 20 
PVP-I treatment (P<0.05).  21 
PCA was used to reduce the dimensionality of the viable cell data, and allowed 22 
the data to be plotted along two principal components (Figure 7).  Four distinct 23 
clusters emerged; cluster 1 containing only untreated 2-D model; cluster 2 was 24 
only PVP-I treated 2-D model; cluster 3 contained CHX treated 2-D model and 25 
PVP-I treated 3-D model; cluster 4 containing untreated and CHX treated 3-D 26 
model. These clusters were statistically distinct (P<0.05). Untreated samples 27 
scored higher on PC1 (x axis), this is also true of CHX treated 3-D model, which 28 
were indistinct from their untreated counterpart. Treated samples generally 29 
scored lower on PC1, which is shown by the directionality arrows. 3-D model 30 
biofilms generally scored higher on PC2 (y axis), with the exception of CHX 31 
 13 
treated 2-D biofilms within cluster 1. Collectively, these data show that 2-D 1 
models undergoing treatment can reveal clear effects from antimicrobial 2 
challenge, whereas 3-D models are not subject to the same extent of dynamic 3 
change.   4 
 5 
  6 
 14 
Discussion 1 
This study set out to test clinically relevant treatments on a newly developed in 2 
vitro inter-kingdom triadic biofilm model that is more representative of the 3 
physical environment and microbial composition of wounds infections. Based on 4 
the methods employed, we report that our new developed wound model 5 
supports significantly greater quantities of microorganisms, and that this  6 
improved structure reduces the effectiveness of widely used topical antimicrobial 7 
agents. Overall, irrespective of the model used, PVP-I treatment was generally 8 
more effective than CHX in reducing bacterial, fungal and inter-kingdom 9 
bioburden. This highlights the need to better understand the biofilm environment, 10 
in particular the importance of mono-, multi-species, or indeed inter-kingdom 11 
biofilms in these infections. 12 
Models that recapitulate complex biofilm related diseases and test antimicrobial 13 
agents are difficult. Moreover, the ways in which these models are interrogated 14 
to generate meaningful data are often flawed. The use of conventional plate 15 
counting is still wide spread despite the inherent bias towards the outcome 16 
antimicrobial challenge. Innovative molecular based methodologies that analyse 17 
viability tend to yield data that is accurate, both qualitatively and quantitatively. 18 
Apparent “complete and efficient killing” phenomenon demonstrated by 19 
conventional microbiological studies of wound biofilms are not unusual (Hill, et 20 
al. 2010, Kart, et al. 2014), including on the agents tested here on methicillin 21 
resistant S. aureus-C. albicans co-cultures and P. aeruginosa only biofilms 22 
(Hoekstra, et al. 2016). However, molecular viability analysis can often reveal a 23 
larger viable population of cells remaining after treatment (Sherry, et al. 2016). 24 
This can be expected, given the nature of the extracellular matrix combined with 25 
viable but non-culturable (VBNC), or persister cells, which occur naturally within 26 
microbial communities.  27 
The novel in vitro interkingdom biofilm model characterised herein consistently 28 
showed higher cell counts and less effectiveness of the topical agents used 29 
compared with biofilms on polystyrene substrates. This may be partially due to 30 
the increased surface area within the cellulose matrix of the novel model. The 31 
comparison against the standardised plastic substrate showed that although 32 
 15 
they are extensively used for many applications (Capita et al. 2014, Kart, et al. 1 
2014, Mottola et al. 2016, Naparstek et al. 2014, Santos et al. 2016), they are 2 
not fully representative of the in vivo situation.  It has been noted previously that 3 
organisms grown with the support of hydrogel matrices are less susceptible to 4 
antimicrobial treatments (Clutterbuck, et al. 2007, Percival, et al. 2007). Within 5 
3-D structures such as these it has previously been noted that varying metabolic 6 
states naturally exist, due to gradients of both oxygen and nutrients (Rani et al. 7 
2007). These gradients are thought to contribute to tolerance of antimicrobials 8 
in biofilms, which could also contribute to the effects seen here. This is indeed a 9 
limitation of widespread 2-D models. In our study, this was especially evident 10 
with the CHX treatment; which although it apparently effective in the 2-D model 11 
showed only a minimal effect on the 3-D matrix probably mainly due to the high 12 
levels of P. aeruginosa within this model, which has been found to be resistant 13 
to CHX at the wound wash concentration (Salami et al. 2006). Interestingly, 14 
taking a PCA approach we showed that the untreated and CHX treated cellulose 15 
models clustered together, indicating there is little change in viable composition, 16 
which is reinforced by the other results described herein. While the proportional 17 
make-up of the 2-D model was roughly equally split between the three species, 18 
in the 3-D cellulose matrix model C. albicans and P. aeruginosa dominated. S. 19 
aureus was present in the cellulose matrix model at approximately 2 × log10 lower, 20 
which is also reflected in SEM imaging. Conversely, P. aeruginosa can be 21 
observed covering the 3-D mesh of the untreated cellulose matrix.  22 
Innovative molecular based methodologies that analyse viability tend to yield 23 
data that is accurate, both qualitatively and quantitatively. These have been used 24 
to scrutinise and evaluate the impact of treatment of wound infections, and are 25 
well described. Early wound model studies used qPCR to investigate 26 
compositional changes within their chronic wound biofilm model (Dowd et al. 27 
2009). PCR has previously been criticised for being too sensitive and 28 
overestimating the population when compared to culture techniques, with this 29 
being attributed to eDNA and the presence of dead cells (Castillo et al. 2006, He 30 
and Jiang 2005). As table 2 illustrates, live/dead PCR is the most expensive 31 
technique used in this work. Although qPCR approaches are more expensive 32 
overall, these methods eliminate the subjectivity and non-specificity that are 33 
 16 
associated with conventional microbiology approaches. Moreover, detrimental 1 
interactions produced by P. aeruginosa phenazines have detriment effects on 2 
hyphal growth and viability, effects difficult to decipher with conventional 3 
approaches (Hogan and Kolter 2002). With our approach, significant differences 4 
were demonstrated here in viability, however there was little difference seen 5 
between the biomass of untreated and treated biofilms (data not shown), which 6 
is consistent with other studies where CHX and PVP-I did not reduce biomass 7 
(Sherry et al. 2013, Tote et al. 2010).  8 
No conclusive clinical studies exist which confirm the effectiveness of CHX in 9 
either diabetic foot ulcer or chronic wound infection. A study using a bioreactor 10 
to form an in vitro multi-species biofilm incorporating Klebsiella pneumoniae, P. 11 
aeruginosa, S. aureus and Enterococcus faecalis concluded that the 12 
effectiveness of CHX in controlling a pre-formed biofilm may be limited, 13 
especially on multi-species biofilms (Touzel et al. 2016). 14 
Similarly, definitive clinical studies for PVP-I are lacking. A recent rat model study 15 
found that P. aeruginosa infected wounds irrigated with PVP-I had reduced 16 
bacterial counts both on the wound surface and within the tissue compared with 17 
irrigation with saline (Kanno et al. 2016). However, this model may be more 18 
relevant to skin preparation prior to surgery than to the management of chronic 19 
wounds. A Cochrane review of the use of antiseptics in pressure ulcers included 20 
PVP-I, but not CHX. The study concluded that the relative effects of systemic 21 
and topical antimicrobial treatments on pressure ulcers are not clear but the 22 
evidence was graded from moderate to low quality (Norman et al. 2015). More 23 
useful is the Cochrane review of antibiotics and antiseptics for venous leg ulcers, 24 
which concludes that while some evidence supports the use of 25 
cadexomer iodine more evidence is required before conclusions can be drawn 26 
about the effectiveness of PVP-I or CHX in healing venous leg ulceration 27 
(O’Meara et al. 2013). 28 
 29 
Conclusions 30 
This study highlights importance creating a polymicrobial in vitro biofilm 31 
reflective of the microflora of wounds, containing both fungal and bacterial 32 
components. Representative 3-D biofilm substrates showed an increased 33 
resistance to antimicrobial wound washes compared to the 2-D plastic surfaces. 34 
 17 
Indeed, PCA analysis was clearly able to discern how the models reacted to 1 
different treatments. The necessity of using multiple viability techniques to 2 
analyse different aspects of the biofilm is also recognised. Singular approaches 3 
often only analyse one aspect of the biofilm, but by combining techniques 4 
multiple outputs can be measured and analysed collectively. In practical terms, 5 
this study shows that our ability to influence wound infections of a polymicrobial 6 
and inter-kingdom nature are limited with simple treatments, particularly given 7 
the resilient capacity of complex biofilms and their potential to remain and 8 
seeding reservoirs. Further studies will be important in trying to maximise the 9 
removal and decontamination of complex wound infections, potentially reducing 10 
patient morbidity and mortality. 11 
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Figure 1 – Antimicrobial wound washes exhibit cidal activity against 1 
polymicrobial 2-D biofilms. Bacterial and fungal biofilms were grown as mono (A) and 2 
triadic cultures (B) in a 2-D model, as previously described. Following development, 3 
biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. 4 
Monospecies (A) and triadic biofilms (B) were assessed by CFU. Viability was also 5 
assessed by the alamarBlue viability assay (C). All testing was carried out in triplicate, 6 
on three separate occasions. Data represents mean ± SD, statistical analysis compared 7 
untreated to treated biofilms (*p<0.05, **p<0.01, ***p<0.001). #Indicates no cell growth. 8 
 9 
Figure 2 – Molecular analysis demonstrates a significant microbial burden 10 
remains within 2-D biofilms following treatment. Bacterial and fungal monospecies 11 
biofilms were grown in a 2-D model, as previously described. Following development, 12 
biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead 13 
PCR was performed and colony-forming equivalents (CFE) were calculated from 14 
standard curves for C. albicans (A), S. aureus (B) and P. aeruginosa (C). Data 15 
represents mean ± SD. * Represents statistical difference in total CFE values and # 16 
represents significant differences between live CFE values (*p<0.05, **p<0.01, 17 
***p<0.001). Data represents CFE values calculated from triplicates carried out on three 18 
separate occasions. 19 
 20 
Figure 3 – Molecular analysis gives insight into cell death in triadic 2-D biofilms, 21 
while SEM reveals complex communities in the triadic model.  Bacterial and fungal 22 
triadic biofilms were grown in a 2-D model, as previously described. Following 23 
development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 
24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were 25 
calculated from standard curves for untreated (A), PVP-I (B) and CHX (C). Data 26 
represents percentage composition calculated from CFE values from triplicates carried 27 
out on three separate occasions. SEM, shown in lower panels, was conducted as 28 
described in the methods. Note P. aeruginosa indicated by a solid white arrow, S. 29 
aureus by white arrow head, C. albicans by a black arrow. C. albicans is present in 30 
predominantly hyphae form; the bacteria can be seen attached to the hyphae. Bars 31 
represent 20 µm on lower magnifications (×1000) and 2 µm at higher magnification 32 
(inset, ×6000).  33 
 34 
Figure 4 – PVP-I shows superior killing activity over CHX on 3-D biofilms. Bacterial 35 
and fungal biofilms were grown as mono (A) and triadic cultures (B) in the 3-D model, 36 
as previously described. Following development, biofilms were washed and treated with 37 
 24 
PVP-I (10%) or CHX (0.05%) for 24 h. Monospecies (A) and triadic biofilms (B) were 1 
assessed by CFU. Viability was also assessed by the alamarBlue viability assay (C). 2 
All testing was carried out in triplicate, on three separate occasions. Data represents 3 
mean ± SD, statistical analysis compared untreated to treated biofilms (*p<0.05, 4 
**p<0.01, ***p<0.001). #Indicates no cell growth. 5 
 6 
Figure 5 - Molecular analysis demonstrates a significant microbial burden with 7 
limited activity of CHX on 3-D biofilms. Bacterial and fungal monospecies biofilms 8 
were grown in the 3-D model, as previously described. Following development, biofilms 9 
were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR 10 
was performed and colony-forming equivalents (CFE) were calculated from standard 11 
curves for C. albicans (A), S. aureus (B) and P. aeruginosa (C). Data represents mean 12 
± SD. * Represents statistical difference in total CFE values and # represents significant 13 
differences between live CFE values (*p<0.05, **p<0.01, ***p<0.001). Data represents 14 
CFE values calculated from triplicates carried out on three separate occasions. 15 
 16 
Figure 6 – Molecular analysis show compositional changes after treatment, 17 
especially with PVP-I, and SEM confirms high levels of growth in the triadic 3-D 18 
model.  Bacterial and fungal triadic biofilms were grown in the 3-D model, as previously 19 
described. Following development, biofilms were washed and treated with PVP-I (10%) 20 
or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-forming 21 
equivalents (CFE) were calculated from standard curves for untreated (A), PVP-I (B) 22 
and CHX (C). Data represents percentage composition calculated from CFE values 23 
from triplicates carried out on three separate occasions. SEM, shown in lower panels, 24 
was conducted as described in the methods. Note P. aeruginosa indicated by a solid 25 
white arrow, S. aureus by white arrow head, C. albicans by a black arrow. In the 3-D 26 
model, C. albicans is seen as mostly yeast; here bacteria and yeast are seen in clusters 27 
upon the cellulose matrix. Bars represent 20 µm on lower magnifications (×1000) and 28 
2 µm at higher magnification (inset, ×6000). 29 
 30 
 31 
Figure 7 – Principal Component Analysis shows little effect of CHX treatment on 32 
cellulose matrix biofilms, whilst treatment of the 2-D model caused a shift to new 33 
clusters. PCA reduces the dimensionality of the data to form clusters. The axes 34 
represent the two principal components of the data which showed the highest variance. 35 
These cluster patterns showed treatment with CHX does not impact cellulose matrix 36 
biofilms, and PVP-I caused a similar compositional change in the 3-D model to that of 37 
 25 
CHX treatment in the 2-D model. ● Untreated 2-D, + Untreated 3-D, ▫ PVP-I 2-D, ▪ PVP-1 
I 3-D, × CHX 2-D,○ CHX 3-D. 2 
